Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Inventory (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Inventory for 16 consecutive years, with $2.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Inventory rose 9.71% year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Sep 2025, up 9.71%, and an annual FY2024 reading of $2.3 million, down 41.32% over the prior year.
  • Inventory was $2.7 million for Q3 2025 at China Pharma Holdings, up from $2.7 million in the prior quarter.
  • Across five years, Inventory topped out at $3.9 million in Q2 2023 and bottomed at $2.3 million in Q4 2024.
  • Average Inventory over 5 years is $3.2 million, with a median of $3.0 million recorded in 2021.
  • The sharpest move saw Inventory soared 31.01% in 2023, then crashed 41.32% in 2024.
  • Year by year, Inventory stood at $2.9 million in 2021, then changed by 0.0% to $2.9 million in 2022, then skyrocketed by 31.01% to $3.9 million in 2023, then crashed by 41.32% to $2.3 million in 2024, then rose by 20.98% to $2.7 million in 2025.
  • Business Quant data shows Inventory for CPHI at $2.7 million in Q3 2025, $2.7 million in Q2 2025, and $2.8 million in Q1 2025.